Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIDATE vs ETHRANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Induction and maintenance of general anesthesia
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Primarily hepatic via cytochrome P450 (CYP2E1); minor metabolism to fluoride ions.
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
Approximately 30-40%, primarily to albumin.
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
Vd: 1.2-2.0 L/kg, indicating extensive distribution into tissues, especially fat.
IV: 100%; IM: >90%; Rectal: ~50% (variable).
By inhalation: 100% as delivered; not administered orally.
No adjustment required; pharmacokinetics unchanged in renal impairment.
No dose adjustment required for GFR >10 m L/min; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation of inorganic fluoride metabolites.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment as metabolism may be decreased.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Induction: 2-5% inspired concentration; Maintenance: 1-3% inspired concentration, adjusted to age and response.
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
Lower inspired concentrations (0.5-2%) recommended due to increased sensitivity and reduced clearance; titrate to effect.
None
None
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
May cause dose-dependent cardiovascular depression,Risk of malignant hyperthermia,Potential for nephrotoxicity due to fluoride release,Hepatotoxicity risk, especially with repeated use,Neurologic effects including seizure activity at high doses
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected susceptibility to malignant hyperthermia,Severe hepatic impairment,Uncontrolled epilepsy
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
No specific food interactions. Patient must follow preoperative fasting guidelines (nil per os, NPO) as directed by anesthesiologist to reduce risk of aspiration.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal hypoxia from maternal hypotension.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Excreted in breast milk in low amounts; M/P ratio not established. Consider benefits of breastfeeding vs. risk of infant exposure. Minimal systemic absorption in infant expected.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
No specific dose adjustments required for pregnancy; however, MAC decreases by approximately 30% during pregnancy due to hormonal changes and increased progesterone. Monitor depth of anesthesia closely.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
ETHRANE (enflurane) is a potent inhalation anesthetic. Its use is limited due to risk of seizures at high doses and potential for nephrotoxicity from fluoride ion release. Avoid in patients with history of seizures or renal impairment. Rapid induction and recovery; use with caution in hypotensive patients due to myocardial depression. Malignant hyperthermia trigger.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
You will receive this anesthesia medication only in a hospital setting under expert supervision.,Possible side effects include nausea, vomiting, shivering, and confusion after waking up.,Tell your doctor if you have a history of seizures, kidney problems, or muscle disorders.,Avoid driving or operating machinery for at least 24 hours after anesthesia.,Do not eat or drink for the time specified by your healthcare team before surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIDATE vs ETHRANE, answered by our medical review team.
AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. ETHRANE is a General Anesthetic that works by Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIDATE and ETHRANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. The standard adult dose of ETHRANE is: 1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIDATE and ETHRANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . ETHRANE is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.